Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
Phase 1/2 Terminated
9 enrolled 11 charts
Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
Phase 1/2 Completed
54 enrolled 18 charts
Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer
Phase 1/2 Terminated
25 enrolled 9 charts
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies
Phase 1/2 Completed
63 enrolled 16 charts
Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML
Phase 1/2 Completed
22 enrolled 14 charts
Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease
Phase 1/2 Completed
38 enrolled 12 charts
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
Phase 1/2 Completed
70 enrolled 26 charts
An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)
Phase 1/2 Terminated
32 enrolled 16 charts
Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant
Phase 1/2 Completed
35 enrolled 13 charts
Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer
Phase 1/2 Terminated
12 enrolled 14 charts
Bu Flu TBI
Phase 1/2 Completed
147 enrolled 19 charts
Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML
Phase 1/2 Completed
40 enrolled 12 charts
LCCC0510
Phase 1/2 Completed
54 enrolled 17 charts
Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Phase 1/2 Terminated
1 enrolled 5 charts
Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer
Phase 1/2 Completed
32 enrolled 9 charts